We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
TIDMEVG
RNS Number : 8922E
Evgen Pharma PLC
11 November 2020
Evgen Pharma plc
("Evgen" or the "Company")
Comment on COVID-19 vaccine announcement
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, notes the recent news that Pfizer have announced the first interim analysis of a Phase III COVID-19 vaccine. Evgen believe that multiple approaches will be needed to curtail this virus and the progress announced earlier this week is a hugely positive development.
As previously announced, Evgen have entered into a Phase II/III trial with the University of Dundee to investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS") including, but not exclusively in patients with suspected COVID-19. The Company confirms that this study is poised to commence recruitment, as announced on 23 October 2020 and will be providing a further update shortly.
The Phase II/III STAR trial (SFX-01 Treatment for Acute Respiratory Infections) has received all the necessary regulatory approvals needed to proceed and patient recruitment will begin shortly. Supplies of SFX-01 have already been delivered to the centre.
Dr Huw Jones, Evgen CEO, commented: "We are pleased to see such progress on a potential vaccine against COVID-19. Recently ARDS has been heavily associated with COVID-19 as it affects the respiratory tract, but it is and will remain a condition in its own right long after we have beaten the pandemic and will continue to be a huge problem for patients. There is a considerable unmet need for effective treatments for ARDS and the outcome of our study will hopefully show how we can use SFX-01 in a serious respiratory condition regardless of the infective agent involved."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook Barry Clare, Chairman Dr Huw Jones, CEO Richard Moulson, CFO finnCap www.finncap.com +44 (0)20 7220 0500 Geoff Nash / Teddy Whiley (Corporate Finance) Alice Lane (ECM) Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7876 Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RESBMBFTMTIBBIM
(END) Dow Jones Newswires
November 11, 2020 02:00 ET (07:00 GMT)
1 Year Evgen Pharma Chart |
1 Month Evgen Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions